Impact of responder definition on the enriched enrollment randomized withdrawal trial design for establishing proof of concept in neuropathic pain
David Hewitt(Glasgow Royal Infirmary), Hao Wang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Paul J. Markovitz(Center for Anxiety and Depression), James A. Bolognese(Cytel (United States)), Arnold R. Gammaitoni(Merck & Co., Inc., Rahway, NJ, USA (United States)), Tony W. Ho(Johns Hopkins University), David Michelson(Loma Linda University Children's Hospital), Gary Herman(Regeneron (United States)), Achilles Alon(Merck & Co., Inc., Rahway, NJ, USA (United States)), Bradley S. Galer(Rapt Therapeutics (United States)), Elizabeth Rosenberg(Merck & Co., Inc., Rahway, NJ, USA (United States)), Miroslav Bačkonja(University of Wisconsin–Madison)
Cited by 63
Related Papers
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
|New England Journal of Medicine|2020|1.8k
Advances in Neuropathic Pain
|Archives of Neurology|2003|1.2k
Sources of variance in 24-hour dietary recall data: implications for nutrition study design and interpretation
|American Journal of Clinical Nutrition|1979|997
Recommendations for the Management of Herpes Zoster
|Clinical Infectious Diseases|2006|842